In recent years, immunotherapy with checkpoint inhibitors targeting T cell co-inhibitory signaling pathways, including programmed death-1/programmed death-ligand 1 (PD-1/PD-L1), is redefining cancer therapy [5]. The gene discussed is PDCD1; the disease is cancer.